In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overNCI, OtherRTOG-0924
CDR0000701128, NCI-2011-02674, NCT01368588

Trial Description

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

Further Study Information

OBJECTIVES:

Primary

  • Demonstrate that prophylactic, neoadjuvant, androgen-deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) of patients with "unfavorable" intermediate-risk or "favorable" high-risk prostate cancer compared to NADT and high-dose prostate (P) and seminal vesicle (SV) radiation therapy (RT) using intensity-modulated RT (IMRT) or external-beam RT (EBRT) with a high-dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost.

Secondary

  • Demonstrate that prophylactic WPRT improves biochemical control.
  • Determine the distant metastasis (DM)-free survival.
  • Determine the cause-specific survival (CSS).
  • Compare acute and late treatment-adverse events between patients receiving NADT and WPRT versus NADT, P, and SV RT.
  • Determine whether health-related quality of life (HRQOL), as measured by the Expanded Prostate Cancer Index Composite (EPIC), significantly worsens with increasing aggressiveness of treatment (i.e., Arm 2, NADT + WPRT).
  • Determine whether more aggressive treatment (Arm 2, NADT + WPRT) is associated with a greater increase in fatigue (PROMIS Fatigue Short Form) from baseline to last week of treatment, and a greater increase in circulating inflammatory markers (IL-1, IL-1ra, IL-6, tumor necrosis factor (TNF)-alpha, and C-reactive protein).
  • Demonstrate an incremental gain in OS and CSS with more aggressive therapy that outweighs any detriments in the primary generic domains of HRQOL (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).
  • Determine whether changes in fatigue from baseline to the next three time points (week prior to RT, last week of treatment, and 3 months after treatment) are associated with changes in circulating cytokines, mood, sleep, and daily activities across the same time points.
  • Collect paraffin-embedded tissue blocks, plasma, whole blood, and urine for planned and future translational research analyses.

OUTLINE: This is a multicenter study. Patients are stratified according to moderate- to high-risk groups as listed in the Disease Characteristics of this abstract, type of radiotherapy boost (IMRT vs brachytherapy [Low-dose rate (LDR) using PPI or HDR]), and duration of androgen-deprivation therapy (short-term [6 months] vs long-term [32 months]). Patients are randomized to 1 of 2 treatment arms.

All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 6 months, and luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy comprising leuprolide acetate, goserelin acetate, buserelin, triptorelin, or degarelix subcutaneously (SC) or intramuscularly (IM) every 1 to 3 months beginning 2 months prior to radiotherapy and continuing for 6 or 32 months.

Radiotherapy begins within 8 weeks after beginning LHRH agonist/antagonist injection.

  • Arm I: Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)* or 3D-conformal radiation therapy (3D-CRT)* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (iodine I 125 or palladium Pd 103 may be used as the radioisotope).
  • Arm II: Patients undergo whole-pelvic radiotherapy (WPRT)* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.

NOTE: * Patients undergoing brachytherapy implant receive 5 weeks of IMRT, 3D-CRT, or WPRT.

Patients may undergo blood and urine sample collection for correlative studies. Primary tumor tissue samples may also be collected.

Patients may complete the Expanded Prostate Cancer Index Composite (EPIC), the PROMIS-Fatigue Short Form, and the EuroQol (EQ-5D) quality-of-life (QOL) questionnaires at baseline and periodically during treatment. Patients who participate in the QOL portion of the study must also agree to periodic blood collection.

After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for 3 years, and then yearly thereafter.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence as determined by one of the following combinations:
  • Gleason score 7-10 + T1c-T2b (palpation) + prostate-specific antigen (PSA) < 50 ng/mL (includes intermediate- and high-risk patients)
  • Gleason score 6 + T2c-T4 (palpation) or > 50% (positive) biopsies + PSA < 50 ng/mL
  • Gleason score 6 + T1c-T2b (palpation) + PSA > 20 ng/mL
  • History and/or physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration
  • Clinically negative lymph nodes as established by imaging (pelvic and/or abdominal CT or MR), (but not by nodal sampling, or dissection) within 90 days prior to registration
  • Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm
  • Patients status post a negative lymph node dissection are not eligible
  • No evidence of bone metastases (M0) on bone scan within 120 days prior to registration
  • Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis
  • Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 12 weeks (90 days) prior to registration
  • Study entry PSA should not be obtained during the following time frames:
  • Ten-day period following prostate biopsy
  • Following initiation of hormonal therapy
  • Within 30 days after discontinuation of finasteride
  • Within 90 days after discontinuation of dutasteride

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-1
  • Absolute neutrophil count (ANC) ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin (Hgb) ≥ 8.0 g/dL (transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable)
  • No prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 3 years (1,095 days) and not in the pelvis
  • E.g., carcinoma in situ of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed
  • No prior hematological (e.g., leukemia, lymphoma, or myeloma) malignancy
  • No severe, active co-morbidity, defined as any of the following:
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
  • Transmural myocardial infarction within the last 6 months
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects or severe liver dysfunction
  • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition
  • Protocol-specific requirements may also exclude immuno-compromised patients
  • HIV testing is not required for entry into this protocol
  • No patients who are sexually active and not willing/able to use medically acceptable forms of contraception
  • No prior allergic reaction to the hormones involved in this protocol

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior radical surgery (prostatectomy) or cryosurgery for prostate cancer
  • No prior pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
  • No prior hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate), estrogens (e.g., diethylstilbestrol (DES) ), or surgical castration (orchiectomy)
  • No prior pharmacologic androgen ablation for prostate cancer unless the onset of androgen ablation is ≤ 45 days prior to the date of registration
  • No finasteride within 30 days prior to registration
  • No dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration
  • No prior or concurrent cytotoxic chemotherapy for prostate cancer
  • Prior chemotherapy for a different cancer is allowable
  • No prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields

Trial Contact Information

Trial Lead Organizations/Sponsors

Radiation Therapy Oncology Group

National Cancer Institute

Mack RoachPrincipal Investigator

Trial Sites

U.S.A.
Alaska
  Anchorage
 Providence Cancer Center
 Matthew C Solhjem Ph: 503-215-6412
  Fairbanks
 Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
 Huong T. Pham Ph: 800-354-9527
Arizona
  Phoenix
 Arizona Oncology - Deer Valley Center
 David G. Brachman Ph: 800-360-6371
  Scottsdale
 Arizona Oncology Services Foundation
 David G. Brachman Ph: 800-360-6371
California
  Auburn
 Auburn Radiation Oncology
 Christopher Jones Ph: 916-454-6500
  Email: cancerinfo@sutterhealth.org
  Cameron Park
 Radiation Oncology Centers - Cameron Park
 Christopher Jones Ph: 916-454-6500
  Email: cancerinfo@sutterhealth.org
  Carmichael
 Mercy Cancer Center at Mercy San Juan Medical Center
 Christopher Jones Ph: 916-454-6500
  Email: cancerinfo@sutterhealth.org
  La Jolla
 Rebecca and John Moores UCSD Cancer Center
 Mack Roach Ph: 877-827-3222
  Email: mroach@radonc.ucsf.edu
  Oakland
 Kaiser Permanente-Oakland
 Samantha A Seaward Ph: 626-564-3455
  Palm Springs
 Desert Regional Medical Center Comprehensive Cancer Center
 Judy M Jackson Ph: 760-416-4730
  Paradise
 Feather River Hospital Cancer Center
 Sam Mazj Ph: 530-876-7995
  Email: haleew@ah.org
  Pomona
 Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
 Swarna S Chanduri Ph: 909-865-9555
  Rancho Cardova
 Kaiser Permanente Medical Center - Rancho Cordova
 Samantha A Seaward Ph: 626-564-3455
  Rohnert Park
 Rohnert Park Cancer Center
 Samantha A Seaward Ph: 626-564-3455
  Roseville
 Radiation Oncology Center - Roseville
 Christopher Jones Ph: 916-454-6500
  Email: cancerinfo@sutterhealth.org
 The Permanente Medical Group-Roseville Radiation Oncology
 Samantha A Seaward Ph: 626-564-3455
  Sacramento
 South Sacramento Cancer Center
 Samantha A Seaward Ph: 626-564-3455
 Sutter Cancer Center
 Christopher Jones Ph: 916-454-6500
  Email: cancerinfo@sutterhealth.org
 University of California Davis Cancer Center
 Richard K. Valicenti Ph: 916-734-3089
  Santa Clara
 Kaiser Permanente Medical Center - Santa Clara Homestead Campus
 Samantha A Seaward Ph: 626-564-3455
 Louis Fehrenbacher Ph: 626-564-3455
  South San Francisco
 Kaiser Permanente Cancer Treatment Center
 Samantha A Seaward Ph: 626-564-3455
  Stanford
 Stanford Cancer Center
 Mark K Buyyounouski Ph: 650-498-7061
  Email: ccto-office@stanford.edu
  Vacaville
 Solano Radiation Oncology Center
 Christopher Jones Ph: 916-454-6500
  Email: cancerinfo@sutterhealth.org
Colorado
  Aurora
 Rocky Mountain Cancer Centers - Aurora
 Keren Sturtz Ph: 888-785-6789
  Denver
 Porter Adventist Hospital
 Keren Sturtz Ph: 888-785-6789
  Greeley
 North Colorado Medical Center
 Keren Sturtz Ph: 888-785-6789
  Longmont
 Hope Cancer Care Center at Longmont United Hospital
 Keren Sturtz Ph: 888-785-6789
  Loveland
 McKee Medical Center
 Keren Sturtz Ph: 888-785-6789
Connecticut
  Bridgeport
 St. Vincent's Medical Center
 Christopher M Iannuzzi Ph: 203-576-6329
  Email: twhite@stvincents.org
  Hartford
 Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
 Samir Narayan Ph: 734-712-3456
  Middletown
 Middlesex Hospital Cancer Center
 Susanna Hong Ph: 860-358-2058
Delaware
  Newark
 Helen F. Graham Cancer Center at Christiana Hospital
 Adam Raben Ph: 302-733-6227
 Adam Raben Ph: 302-733-6227
Florida
  Jacksonville
 Baptist Cancer Institute - Jacksonville
 Michael R Olson Ph: 904-202-7051
  Jascksonville
 Integrated Community Oncology Network - Baptist South
 Michael R Olson Ph: 904-202-7051
  Jupiter
 Ella Milbank Foshay Cancer Center at Jupiter Medical Center
 Michael Schwartz Ph: 305-674-2625
  Email: info@msccop.com
  Palatka
 Cancer Specialists of North Florida-Putnam
 Michael R Olson Ph: 904-202-7051
  Tampa
 Veterans Affairs Medical Center - Tampa
 Babu Zachariah Ph: 800-456-7121
  Email: canceranswers@moffitt.org
Georgia
  Atlanta
 Georgia Cancer Center for Excellence at Grady Memorial Hospital
 Ashesh B. Jani Ph: 404-778-1868
 Piedmont Hospital
 Adam W Nowlan Ph: 404-425-7943
  Email: ORS@piedmont.org
 Saint Joseph's Hospital of Atlanta
 Ashesh B. Jani Ph: 404-778-1868
 Winship Cancer Institute of Emory University
 Ashesh B. Jani Ph: 404-778-1868
  Columbus
 John B. Amos Cancer Center
 Douglas F. Ciuba Ph: 706-660-6404
  Decatur
 Veterans Affairs Medical Center - Atlanta (Decatur)
 Scott Edelman Ph: 404-321-6111ext7632
  Fayetteville
 Piedmont Fayette Hospital
 Adam W Nowlan Ph: 404-425-7943
  Email: ORS@piedmont.org
  Savannah
 Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
 John A Pablo Ph: 912-819-5704
Hawaii
  Honolulu
 Queen's Cancer Institute at Queen's Medical Center
 Paul A. DeMare Ph: 808-545-8548
Idaho
  Boise
 Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
 Samir Narayan Ph: 734-712-3456
  Post Falls
 Kootenai Cancer Center - Post Falls
 Benjamin Thomas Marchello Ph: 800-648-6274
Illinois
  Chicago
 John H. Stroger, Jr. Hospital of Cook County
 Jagdish V Thakrar Ph: 312-864-6000
 Louis A. Weiss Memorial Hospital
 Keith L. Shulman Ph: 773-564-5044
  Rockford
 Advanced Care and Treatment Medical Group, PC
 Harvey Eric Einhorn Ph: 779-696-9400
  Email: cancercare@swedishamerican.org
  Urbana
 Carle Cancer Center at Carle Foundation Hospital
 Ronald A Sapiente Ph: 800-446-5532
Indiana
  Fort Wayne
 Parkview Regional Cancer Center at Parkview Health
 Brian K Chang Ph: 260-373-8888
  Email: parkviewresearch@parkview.com
 Radiation Oncology Associates Southwest
 Brian K Chang Ph: 260-373-8888
  Email: parkviewresearch@parkview.com
Iowa
  Ames
 McFarland Clinic, PC
 Joseph James Merchant Ph: 515-239-2621
Kansas
  Topeka
 Cotton-O'Neil Cancer Center
 David E Einspahr Ph: 785-270-4963
  Wichita
 Via Christi Cancer Center at Via Christi Regional Medical Center
 Shaker R. Dakhil Ph: 316-262-4467
Louisiana
  Baton Rouge
 Mary Bird Perkins Cancer Center - Baton Rouge
 Robert W Veith Ph: 504-568-2428
  Email: emede1@lsuhsc.edu
  New Orleans
 Ochsner Cancer Institute at Ochsner Clinic Foundation
 Troy G. Scroggins Ph: 888-562-4763
 Touro Infirmary
 Robert W Veith Ph: 504-568-2428
  Email: emede1@lsuhsc.edu
 Tulane Cancer Center at Tulane University Hospital and Clinic
 William R. Robinson Ph: 504-988-6121
Maryland
  Annapolis
 DeCesaris Cancer Institute at Anne Arundel Medical Center
 Angel E. Torano Ph: 443-481-1320
  Email: kbodenhorn@aahs.org
  Baltimore
 Greenebaum Cancer Center at University of Maryland Medical Center
 Young Kwok Ph: 800-888-8823
 St. Agnes Hospital Cancer Center
 Richard S. Hudes Ph: 410-368-2910
  Columbia
 Central Maryland Oncology Center
 Young Kwok Ph: 800-888-8823
  Glen Burnie
 Tate Cancer Center at Baltimore Washington Medical Center
 Young Kwok Ph: 800-888-8823
  Salisbury
 Peninsula Regional Medical Center
 Matthew L Snyder Ph: 866-922-6237
Massachusetts
  Fall River
 Hudner Oncology Center at Saint Anne's Hospital - Fall River
 Michele Albert Ph: 508-674-5600ext2515
  Hyannis
 Davenport-Mugar Cancer Center at Cape Cod Hospital
 Daniel J Canaday Ph: 508-862-5799
Michigan
  Ann Arbor
 Saint Joseph Mercy Cancer Center
 Samir Narayan Ph: 734-712-3456
  Dearborn
 Oakwood Cancer Center at Oakwood Hospital and Medical Center
 Samir Narayan Ph: 734-712-3456
  Detroit
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Samir Narayan Ph: 734-712-3456
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Gilbert D Padula Ph: 616-685-5225
 Lacks Cancer Center at Saint Mary's Health Care
 Gilbert D Padula Ph: 616-685-5225
  Livonia
 St. Mary Mercy Hospital
 Samir Narayan Ph: 734-712-3456
  Muskegon
 Mercy General Health Partners
 Gilbert D Padula Ph: 616-685-5225
  Pontiac
 St. Joseph Mercy Oakland
 Samir Narayan Ph: 734-712-3456
  Saginaw
 Seton Cancer Institute at Saint Mary's - Saginaw
 Samir Narayan Ph: 734-712-3456
  Warren
 St. John Macomb Hospital
 Samir Narayan Ph: 734-712-3456
Minnesota
  Bemidji
 MeritCare Bemidji
 Preston D. Steen Ph: 701-234-6161
  Duluth
 St. Luke's Hospital Cancer Care Center
 Steven R Bonin Ph: 888-823-5923
  Email: ctsucontact@westat.com
Mississippi
  Jackson
 University of Mississippi Cancer Clinic
 Srinivasan Vijayakumar Ph: 601-815-6700
Missouri
  Saint Louis
 Barnes-Jewish West County Hospital
 Jeff M. Michalski Ph: 800-600-3606
  Email: info@siteman.wustl.edu
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Jeff M. Michalski Ph: 800-600-3606
  Email: info@siteman.wustl.edu
 Jeff M. Michalski Ph: 800-600-3606
  Email: info@siteman.wustl.edu
  Saint Peters
 Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - St. Peters
 Jeff M. Michalski Ph: 800-600-3606
  Email: info@siteman.wustl.edu
Montana
  Billings
 Billings Clinic Cancer Center - 801 N 29th Street
 Benjamin Thomas Marchello Ph: 800-648-6274
  Great Falls
 Benefis Sletten Cancer Institute
 Benjamin Thomas Marchello Ph: 800-648-6274
New Hampshire
  Lebanon
 Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
 Alan C. Hartford Ph: 800-639-6918
  Email: cancer.research.nurse@dartmouth.edu
New Jersey
  Egg Harbor Township
 AtlantiCare Surgery Center
 James C Wurzer Ph: 609-748-7200
New York
  Brooklyn
 New York Methodist Hospital
 Sameer Rafla-Demetrious Ph: 718-780-5240
North Carolina
  Durham
 Duke Cancer Institute
 W. Robert Lee Ph: 888-275-3853
  Morehead City
 Coleman Radiation Oncology Center at Carter General Hospital
 Michael A Papagikos Ph: 910-251-1839
  Raleigh
 Rex Cancer Center at Rex Hospital
 Leroy G Hoffman Ph: 919-784-7209
  Supply
 South Atlantic Radiation Oncology, LLC
 Michael A Papagikos Ph: 910-251-1839
  Wilmington
 Coastal Carolina Radiation Oncology Center
 Michael A Papagikos Ph: 910-251-1839
  Winston-Salem
 Wake Forest University Comprehensive Cancer Center
 Bart Frizzell Ph: 336-713-6771
North Dakota
  Fargo
 Roger Maris Cancer Center at MeritCare Hospital
 Preston D. Steen Ph: 701-234-6161
Ohio
  Akron
 McDowell Cancer Center at Akron General Medical Center
 Mitchell Lee Fromm Ph: 330-344-6348
 Summa Center for Cancer Care at Akron City Hospital
 Charles A Kunos Ph: 330-375-6101
  Barberton
 Barberton Citizens Hospital
 Charles A Kunos Ph: 330-375-6101
  Chardon
 Geauga Regional Hospital
 Rodney J Ellis Ph: 800-641-2422
  Chillicothe
 Adena Regional Medical Center
 Mark J Becker Ph: 614-566-4475
  Cleveland
 Case Comprehensive Cancer Center
 Rodney J Ellis Ph: 800-641-2422
  Columbus
 Zangmeister Center
 Mark J Becker Ph: 614-566-4475
  Elyria
 Mercy Cancer Center - Elyria
 Rodney J Ellis Ph: 800-641-2422
  Medina
 Summa Health Center at Lake Medina
 Charles A Kunos Ph: 330-375-6101
  Mentor
 Lake/University Ireland Cancer Center
 Rodney J Ellis Ph: 800-641-2422
  Middleburg Heights
 Southwest General Health Center
 Rodney J Ellis Ph: 800-641-2422
  Orange Village
 UHHS Chagrin Highlands Medical Center
 Rodney J Ellis Ph: 800-641-2422
  Portsmouth
 Southern Ohio Medical Center Cancer Center
 Mark J Becker Ph: 614-566-4475
  Ravenna
 Robinson Radiation Oncology
 Mitchell Lee Fromm Ph: 330-344-6348
  Sandusky
 University Hospitals Ireland Cancer Center at Firelands Regional Medical Center
 Rodney J Ellis Ph: 800-641-2422
  Westlake
 UHHS Westlake Medical Center
 Rodney J Ellis Ph: 800-641-2422
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Terence S. Herman Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Oregon
  Clackamas
 Clackamas Radiation Oncology Center
 Matthew C Solhjem Ph: 503-215-6412
  Portland
 Providence Cancer Center at Providence Portland Medical Center
 Matthew C Solhjem Ph: 503-215-6412
 Providence St. Vincent Medical Center
 Matthew C Solhjem Ph: 503-215-6412
Pennsylvania
  Abington
 Rosenfeld Cancer Center at Abington Memorial Hospital
 Wayne H Pinover Ph: 215-481-2402
  Gettysburg
 Adams Cancer Center
 Amit B. Shah Ph: 877-441-7957
  Hanover
 Cherry Tree Cancer Center
 Amit B. Shah Ph: 877-441-7957
  Philadelphia
 Fox Chase Cancer Center - Philadelphia
 Eric Horwitz Ph: 215-728-4790
  West Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Albert Yuen Ph: 610-988-9323
  York
 WellSpan Health
 Amit B. Shah Ph: 877-441-7957
South Carolina
  Greenville
 Cancer Centers of the Carolinas - Faris Road
 David L Grisell Ph: 864-241-6251
 CCOP - Greenville
 David L Grisell Ph: 864-241-6251
  Greer
 Gibbs Cancer Center-Pelham
 Patricia C Griffin Ph: 800-486-5941
  Hilton Head Island
 Hilton Head Radiation Oncology Center
 John A Pablo Ph: 912-819-5704
  Seneca
 Cancer Centers of the Carolinas - Seneca
 David L Grisell Ph: 864-241-6251
  Spartanburg
 Cancer Centers of the Carolinas - Spartanburg
 David L Grisell Ph: 864-241-6251
 Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
 Patricia C Griffin Ph: 800-486-5941
Tennessee
  Chattanooga
 Erlanger Cancer Center at Erlanger Hospital - Baroness
 Donald H. Chamberlain Ph: 423-698-2050
  Kingsport
 Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
 Asheesh Shipstone Ph: 423-578-8538
Texas
  Galveston
 University of Texas Medical Branch
 Martin Colman Ph: 409-772-1950
  Email: clinical.research@utmb.edu
  League City
 UTMB Cancer Center at Victory Lakes
 Martin Colman Ph: 409-772-1950
  Email: clinical.research@utmb.edu
  San Antonio
 University of Texas Health Science Center at San Antonio
 Tony Y. Eng Ph: 210-567-0653
  Email: che@uthscsa.edu
Utah
  American Fork
 American Fork Hospital
 R. Jeffrey Lee Ph: 801-507-3950
  Murray
 Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
 R. Jeffrey Lee Ph: 801-507-3950
  Provo
 Utah Valley Regional Medical Center - Provo
 R. Jeffrey Lee Ph: 801-507-3950
  Saint George
 Dixie Regional Medical Center - East Campus
 R. Jeffrey Lee Ph: 801-507-3950
  Salt Lake City
 Huntsman Cancer Institute at University of Utah
 Jonathan D Tward Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
 Utah Cancer Specialists at UCS Cancer Center
 R. Jeffrey Lee Ph: 801-507-3950
Vermont
  Burlington
 Fletcher Allen Health Care - Medical Center Campus
 Harold James Wallace Ph: 802-656-8990
  Saint Johnsbury
 Norris Cotton Cancer Center - North
 Alan C. Hartford Ph: 800-639-6918
  Email: cancer.research.nurse@dartmouth.edu
Virginia
  Charlottesville
 University of Virginia Cancer Center
 Timothy N Showalter Ph: 434-243-6143
  Hampton
 Sentara Cancer Institute at Sentara CarePlex Hospital
 Mark E Shaves Ph: 757-388-2406
  Norfolk
 Sentara Cancer Institute at Sentara Norfolk General Hospital
 Mark E Shaves Ph: 757-388-2406
  Virginia Beach
 Coastal Cancer Center at Sentara Virginia Beach General Hospital
 Mark E Shaves Ph: 757-388-2406
Washington
  Federal Way
 St. Francis Hospital
 Huong T. Pham Ph: 800-354-9527
  Seattle
 CCOP - Virginia Mason Research Center
 Huong T. Pham Ph: 800-354-9527
  Vancouver
 Southwest Washington Medical Center Cancer Center
 Matthew C Solhjem Ph: 503-215-6412
  Yakima
 North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
 Sean F. Cleary Ph: 877-902-3324
Wisconsin
  Appleton
 Fox Valley Surgical Associates at Appleton Medical Center
 Michael E Ray Ph: 920-380-1500
  Eau Claire
 Luther Midlelfort Hospital
 Sakti Chakrabarti Ph: 715-838-6356
  Green Bay
 St. Mary's Hospital Medical Center - Green Bay
 James L Leenstra Ph: 920-433-8889
 St. Vincent Hospital Regional Cancer Center
 James L Leenstra Ph: 920-433-8889
 Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
 Mitchell H. Pincus Ph: 800-252-2990
  La Crosse
 Franciscan Skemp Healthcare - La Crosse Campus
 David J Schwartz Ph: 608-392-9462
  Email: MMCCOP@parknicollet.com
 Gundersen Lutheran Center for Cancer and Blood
 Collin D Driscoll Ph: 608-775-2385
  Email: cancerctr@gundluth.org
  Marinette
 Bay Area Cancer Care Center at Bay Area Medical Center
 James L Leenstra Ph: 920-433-8889
  Mequon
 Columbia Saint Mary's Hospital - Ozaukee
 Craig A Schulz Ph: 414-326-2675
  Email: clinicaltrials@columbia-stmarys.org
  Milwaukee
 Columbia-Saint Mary's Cancer Care Center
 Craig A Schulz Ph: 414-326-2675
  Email: clinicaltrials@columbia-stmarys.org
 Froedtert Hospital and Medical College of Wisconsin
 Colleen A. Lawton Ph: 414-805-4380
 Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
 Mitchell H. Pincus Ph: 800-252-2990
  Racine
 All Saints Cancer Center at Wheaton Franciscan Healthcare
 James H. Taylor Ph: 414-874-4541
  Email: Kelli.holton@wfhc.org
  Sheboygan
 Vince Lombardi Cancer Clinic - Sheboygan
 Mitchell H. Pincus Ph: 800-252-2990
  Sturgeon Bay
 Door County Cancer Center at Door County Memorial Hospital
 James L Leenstra Ph: 920-433-8889
  Summit
 Aurora Medical Center
 Mitchell H. Pincus Ph: 800-252-2990
  West Allis
 Aurora Women's Pavilion of West Allis Memorial Hospital
 Mitchell H. Pincus Ph: 800-252-2990
Canada
Alberta
  Calgary
 Tom Baker Cancer Centre - Calgary
 Michael A Sia Ph: 403-521-3433
  Edmonton
 Cross Cancer Institute at University of Alberta
 Brita L Danielson Ph: 780-432-8500
Newfoundland
  St. John's
 Doctor H. Bliss Murphy Cancer Centre
 John W Thoms Ph: 709-777-7589
Saskatchewan
  Regina
 Allan Blair Cancer Centre at Pasqua Hospital
 Evgeny Sadikov Ph: 306-766-2213
  Saskatoon
 Saskatoon Cancer Centre at the University of Saskatchewan
 Ali A El-Gayed Ph: 306-655-2914

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01368588
ClinicalTrials.gov processed this data on June 04, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top